PPARA and steatosis: The administration of PPARα agonists have been shown to attenuate MCD-induced hepatic TG accumulation [32], and to upregulate the mRNA of liver FABP and β-oxidation enzymes, thereby reducing hepatic TG and preventing steatosis in mice [33].